Vitrolife AB (publ) (VITR) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Vitrolife Q3 2025 earnings call. For the first part of the presentation, participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Please start by asking one question followed by a follow-up question. It's then fine to queue up again for more questions. Now I will hand the conference over to CEO Bronwyn Brophy and Per Eerskog. Please go ahead. Good morning, everyone. I would like to welcome you to the Vitralife Group Q3 2025 Earnings Report. My name is Bronwyn O'Connor and I'm joined this morning by our new CFO, Pad Iadarsgog. So I will now move you on to the first slide with our Q3 2025 highlights. I would like to start by highlighting three key achievements during the quarter. The first highlight is that we delivered 5% organic growth in local currencies, excluding discontinued business, despite the fact that the reproductive health industry as a whole has continued to face substantial macroeconomic and geopolitical challenges during the quarter. The second highlight I would like to bring to your attention is our growth in Americas. Sales increased by 11% in local currencies with strong growth across the entire portfolio and in all markets in the regions. And finally, we delivered strong operating cash flow of 255 million SEC related to positive contributions from our networking capital. We'll now move to the key financial highlights. So starting with the market, conditions remain challenging in some of the key markets in the IVF industry. However, we did see some small and early signs of recovery in Americas. In EMEA, Western Europe is performing well. However, the market in the Middle East remains impacted by the geopolitical situation. AP...